A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The Stage 1 of this phase 2 study is an open-label single ascending dose (SAD) study to
assess the efficacy and safety of CBL-514 in participants with Edematous Fibrosclerotic
Panniculopathy (EFP) cellulite.